FAB 001

Drug Profile

FAB 001

Alternative Names: FAB001; MUT-056399

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mutabilis
  • Developer FAB Pharma
  • Class Antibacterials; Benzamides; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in France (IV, Infusion)
  • 12 Sep 2012 Antimicrobial data from a Preclinical trial in Acinetobacter infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
  • 17 Sep 2011 Pharmacokinetics data from a preclinical trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top